Telomeric recombination induced by dysfunctional telomeres

Molecular Biology of the Cell

Volumn 22, Issue 2, 2011, Pages 179-188

  Brault, Marie Eve ^a,b   Autexier, Chantal ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN; PROTEIN POT1; PROTEIN TIN2; PROTEIN TPP1; RAP1 PROTEIN; RNA; TELOMERASE; TELOMERIC REPEAT BINDING FACTOR 1; TELOMERIC REPEAT BINDING FACTOR 2; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; DNA DAMAGE; GENE EXPRESSION; HUMAN; HUMAN CELL; MUTANT; MUTANT HUMAN TELOMERASE RNA TEMPLATE; PRIORITY JOURNAL; SISTER CHROMATID; TELOMERE; TELOMERE DYSFUNCTION; TELOMERIC RECOMBINATION;

BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA, CIRCULAR; DNA-BINDING PROTEINS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUTATION; PROTEIN-SERINE-THREONINE KINASES; RECOMBINATION, GENETIC; SISTER CHROMATID EXCHANGE; TELOMERASE; TELOMERE; TELOMERIC REPEAT BINDING PROTEIN 1; TUMOR SUPPRESSOR PROTEINS;

EID: 78751525402     PISSN: 10591524     EISSN: 19394586     Source Type: Journal    
DOI: 10.1091/mbc.E10-02-0173     Document Type: Article

References (62)

1. Autexier C, Lue NF (2006). The structure and function of telomerase reverse transcriptase. Annu Rev Biochem 75, 493-517.
2. Bechard LH, Butuner BD, Peterson GJ, McRae W, Topcu Z, McEachern MJ (2009). Mutant telomeric repeats in yeast can disrupt the negative regulation of recombination-mediated telomere maintenance and create an alternative lengthening of telomeres-like phenotype. Mol Cell Biol 29, 626-639.
3. Bechter OE, Zou Y, Walker W, Wright WE, Shay JW (2004). Telomeric recombination in mismatch repair deficient human colon cancer cells after telomerase inhibition. Cancer Res 64, 3444-3451.
4. Bianchi A, Stansel RM, Fairall L, Griffith JD, Rhodes D, de Lange T (1999). TRF1 binds a bipartite telomeric site with extreme spatial flexibility. EMBO J 18, 5735-5744.
5. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR (1995). Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 14, 4240-4248
6. Celli GB, Denchi EL, de Lange T (2006). Ku70 stimulates fusion of dysfunctional telomeres yet protects chromosome ends from homologous recombination. Nat Cell Biol 8, 885-890.
7. Cerone MA, Autexier C, Londono-Vallejo JA, Bacchetti S (2005). A human cell line that maintains telomeres in the absence of telomerase and of key markers of ALT. Oncogene 24, 7893-7901.
8. Cerone MA, Londono-Vallejo JA, Autexier C (2006). Mutated telomeres sensitize tumor cells to anticancer drugs independently of telomere shortening and mechanisms of telomere maintenance. Oncogene 25, 7411-7420.
9. Cerone MA, Londono-Vallejo JA, Bacchetti S (2001). Telomere maintenance by telomerase and by recombination can coexist in human cells. Hum Mol Genet 10, 1945-1952.
10. Cesare AJ, Griffith JD (2004). Telomeric DNA in ALT cells is characterized by free telomeric circles and heterogeneous t-loops. Mol Cell Biol 24, 9948-9957.
11. Cesare AJ, Reddel RR (2008). Telomere uncapping and alternative lengthening of telomeres. Mech Ageing Dev 129, 99-108.
12. Chang S, Khoo CM, Naylor ML, Maser RS, DePinho RA (2003). Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. Genes Dev 17, 88-100.
13. Chen Q, Ijpma A, Greider CW (2001). Two survivor pathways that allow growth in the absence of telomerase are generated by distinct telomere recombination events. Mol Cell Biol 21, 1819-1827.
14. Chen YJ et al. (2006). Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res 66, 6473-6476.
15. Costa A et al. (2006). Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res 66, 8918-8924.
16. Cristofari G, Lingner J (2006). Telomere length homeostasis requires that telomerase levels are limiting. EMBO J 25, 565-574.
17. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretzki G, Carter NP, Jackson SP (2003). A DNA damage checkpoint response in telomere-initiated senescence. Nature 426, 194-198.
18. Draskovic I, Arnoult N, Steiner V, Bacchetti S, Lomonte P, Londono-Vallejo A (2009). Probing PML body function in ALT cells reveals spatiotemporal requirements for telomere recombination. Proc Natl Acad Sci USA 106, 15726-15731.
19. Dunham MA, Neumann AA, Fasching CL, Reddel RR (2000). Telomere maintenance by recombination in human cells. Nat Genet 26, 447-450.
20. Fasching CL, Bower K, Reddel RR (2005). Telomerase-independent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies. Cancer Res 65, 2722-2729.
21. Goldkorn A, Blackburn EH (2006). Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells. Cancer Res 66, 5763-5771.
22. Grandin N, Damon C, Charbonneau M (2001). Cdc13 prevents telomere uncapping and Rad50-dependent homologous recombination. EMBO J 20, 6127-6139.
23. Grobelny JV, Kulp-McEliece M, Broccoli D (2001). Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening of telomeres (ALT) pathway. Hum Mol Genet 10, 1953-1961.
24. Guiducci C, Anglana M, Wang A, Bacchetti S (2001a). Transient expression of wild-type or biologically inactive telomerase allows the formation of artificial telomeres in mortal human cells. Exp Cell Res 265, 304-311.
25. Guiducci C, Cerone MA, Bacchetti S (2001b). Expression of mutant telomerase in immortal telomerase-negative human cells results in cell cycle deregulation, nuclear and chromosomal abnormalities and rapid loss of viability. Oncogene 20, 714-725.
26. Hahn WC (1999). Inhibition of telomerase limits the growth of human cancer cells. Nature Med 5, 1164-1170.
27. Hakin-Smith V, Jellinek DA, Levy D, Carroll T, Teo M, Timperley WR, McKay MJ, Reddel RR, Royds JA (2003). Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 361, 836-838.
28. Hande MP, Samper E, Lansdorp P, Blasco MA (1999). Telomere length dynamics and chromosomal instability in cells derived from telomerase null mice. J Cell Biol 144, 589-601.
29. He H, Multani AS, Cosme-Blanco W, Tahara H, Ma J, Pathak S, Deng Y, Chang S (2006). POT1b protects telomeres from end-to-end chromosomal fusions and aberrant homologous recombination. EMBO J 25, 5180-5190.
30. Henson JD, Reddel RR (2010). Assaying and investigating alternative lengthening of telomeres activity in human cells and cancers. FEBS Lett 584, 3800-3811.
31. Iyer S, Chadha AD, McEachern MJ (2005). A mutation in the STN1 gene triggers an alternative lengthening of telomere-like runaway recombinational telomere elongation and rapid deletion in yeast. Mol Cell Biol 25, 8064-8073.
32. Kim MM, Rivera MA, Botchkina IL, Shalaby R, Thor AD, Blackburn EH (2001). A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation. Proc Natl Acad Sci USA 98, 7982-7987.
33. Li S, Rosenberg JE, Donjacour AA, Botchkina IL, Hom YK, Cunha GR, Blackburn EH (2004). Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and anti-telomerase short-interfering RNA. Cancer Res 64, 4833-4840.
34. Loayza D, Parsons H, Donigian J, Hoke K, de Lange T (2004). DNA binding features of human POT1: a nonamer 5′-TAGGGTTAG-3′ minimal binding site, sequence specificity, and internal binding to multimeric sites. J Biol Chem 279, 13241-13248.
35. Londono-Vallejo JA, Der-Sarkissian H, Cazes L, Bacchetti S, Reddel RR (2004). Alternative lengthening of telomeres is characterized by high rates of telomeric exchange. Cancer Res 64, 2324-2327.
36. Makarov VL, Hirose Y, Langmore JP (1997). Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell 88, 657-666.
37. Marciniak RA, Cavazos D, Montellano R, Chen Q, Guarente L, Johnson FB (2005). A novel telomere structure in a human alternative lengthening of telomeres cell line. Cancer Res 65, 2730-2737.
38. Marie-Egyptienne DT, Brault ME, Nimmo GA, Londono-Vallejo JA, Autexier C (2009). Growth defects in mouse telomerase RNA-deficient cells expressing a template-mutated mouse telomerase RNA. Cancer Lett 275, 266-276.
39. Marusic L, Anton M, Tidy A, Wang P, Villeponteau B, Bacchetti S (1997). Reprogramming of telomerase by expression of mutant telomerase RNA template in human cells leads to altered telomeres that correlate with reduced cell viability. Mol Cell Biol 17, 6394-6401.
40. Morrish TA, Greider CW (2009). Short telomeres initiate telomere recombination in primary and tumor cells. PLoS Genet 5, e1000357.
41. Niida H, Shinkai Y, Hande MP, Matsumoto T, Takehara S, Tachibana M, Oshimura M, Lansdorp PM, Furuichi Y (2000). Telomere maintenance in telomerase-deficient mouse embryonic stem cells: characterization of an amplified telomeric DNA. Mol Cell Biol 20, 4115-4127.
42. Ogino H, Nakabayashi K, Suzuki M, Takahashi E, Fujii M, Suzuki T, Ayusawa D (1998). Release of telomeric DNA from chromosomes in immortal human cells lacking telomerase activity. Biochem Biophys Res Commun 248, 223-227.
43. Olovnikov AM (1973). A theory of marginotomy. J Theor Biol 41, 181-190.
44. Palm W, de Lange T (2008). How shelterin protects mammalian telomeres. Annu Rev Genet 42, 301-334.
45. Park KH et al. (1998). Telomerase activity and telomere lengths in various cell lines: changes of telomerase activity can be another method for chemosensitivity evaluation. Int J Oncol 13, 489-495.
46. Perrem K, Colgin LM, Neumann AA, Yeager TR, Reddel RR (2001). Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells. Mol Cell Biol 21, 3862-3875.
47. Pickett HA, Cesare AJ, Johnston RL, Neumann AA, Reddel RR (2009). Control of telomere length by a trimming mechanism that involves generation of t-circles. EMBO J 28, 799-809.
48. Sfeir A, Kabir S, van Overbeek M, Celli GB, de Lange T (2010). Loss of Rap1 induces telomere recombination in the absence of NHEJ or a DNA damage signal. Science 327, 1657-1661.
49. Shay JW, Bacchetti S (1997). A survey of telomerase activity in human cancer. Eur J Cancer 33, 787-791.
50. Smogorzewska A, de Lange T (2002). Different telomere damage signaling pathways in human and mouse cells. EMBO J 21, 4338-4348.
51. Stohr BA, Blackburn EH (2008). ATM mediates cytotoxicity of a mutant telomerase RNA in human cancer cells. Cancer Res 68, 5309-5317.
52. Takai H, Smogorzewska A, de Lange T (2003). DNA damage foci at dysfunctional telomeres. Curr Biol 13, 1549-1556.
53. Teng SC, Chang J, McCowan B, Zakian VA (2000). Telomerase-independent lengthening of yeast telomeres occurs by an abrupt Rad50p-dependent, Rif-inhibited recombinational process. Mol Cell 6, 947-952.
54. Teng SC, Zakian VA (1999). Telomere-telomere recombination is an efficient bypass pathway for telomere maintenance in Saccharomyces cerevisiae. Mol Cell Biol 19, 8083-8093.
55. Tokutake Y, Matsumoto T, Watanabe T, Maeda S, Tahara H, Sakamoto S, Niida H, Sugimoto M, Ide T, Furuichi Y (1998). Extra-chromosomal telomere repeat DNA in telomerase-negative immortalized cell lines. Biochem Biophys Res Commun 247, 765-772.
56. Underwood DH, Carroll C, McEachern MJ (2004). Genetic dissection of the Kluyveromyces lactis telomere and evidence for telomere capping defects in TER1 mutants with long telomeres. Eukaryot Cell 3, 369-384.
57. Verdun RE, Karlseder J (2006). The DNA damage machinery and homologous recombination pathway act consecutively to protect human telomeres. Cell 127, 709-720.
58. Wang RC, Smogorzewska A, de Lange T (2004). Homologous recombination generates T-loop-sized deletions at human telomeres. Cell 119, 355-368.
59. Watson JD (1972). Origin of concatameric T4 DNA. Nature New Biol 239, 197-201.
60. Wu L et al. (2006). Pot1 deficiency initiates DNA damage checkpoint activation and aberrant homologous recombination at telomeres. Cell 126, 49-62.
61. Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR (1999). Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 59, 4175-4179.
62. Zhang X, Mar V, Harrington L, Robinson MO (1999). Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 13, 2388-2399.